MYB and CD4+/CD56+ hematodermic neoplasm: Aberrant MYB binding could cause dysregulated expression of these genes, leading to loss of cell cycle control and contributing to BPDCN pathogenesis, since cycling is normally inhibited in dendritic progenitors undergoing terminal pDC differentiation (17).